Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Type of study
Language
Publication year range
1.
Front Immunol ; 13: 958801, 2022.
Article in English | MEDLINE | ID: mdl-36091002

ABSTRACT

Fatal influenza (flu) virus infection often activates excessive inflammatory signals, leading to multi-organ failure and death, also referred to as cytokine storm. PPARγ (Peroxisome proliferator-activated receptor gamma) agonists are well-known candidates for cytokine storm modulation. The present study identified that influenza infection reduced PPARγ expression and decreased PPARγ transcription activity in human alveolar macrophages (AMs) from different donors. Treatment with PPARγ agonist Troglitazone ameliorated virus-induced proinflammatory cytokine secretion but did not interfere with the IFN-induced antiviral pathway in human AMs. In contrast, PPARγ antagonist and knockdown of PPARγ in human AMs further enhanced virus-stimulated proinflammatory response. In a mouse model of influenza infection, flu virus dose-dependently reduced PPARγ transcriptional activity and decreased expression of PPARγ. Moreover, PPARγ agonist troglitazone significantly reduced high doses of influenza infection-induced lung pathology. In addition, flu infection reduced PPARγ expression in all mouse macrophages, including AMs, interstitial macrophages, and bone-marrow-derived macrophages but not in alveolar epithelial cells. Our results indicate that the influenza virus specifically targets the PPARγ pathway in macrophages to cause acute injury to the lung.


Subject(s)
Antiviral Agents , Influenza, Human , Lung , Macrophages , PPAR gamma , Troglitazone , Acute Lung Injury/drug therapy , Acute Lung Injury/genetics , Acute Lung Injury/immunology , Animals , Antiviral Agents/immunology , Antiviral Agents/therapeutic use , Cytokine Release Syndrome/drug therapy , Cytokine Release Syndrome/genetics , Cytokine Release Syndrome/immunology , Humans , Influenza, Human/drug therapy , Influenza, Human/genetics , Influenza, Human/immunology , Lung/immunology , Macrophages/immunology , Mice , Orthomyxoviridae , Orthomyxoviridae Infections/drug therapy , Orthomyxoviridae Infections/genetics , Orthomyxoviridae Infections/immunology , Orthomyxoviridae Infections/virology , PPAR gamma/agonists , PPAR gamma/genetics , PPAR gamma/immunology , Troglitazone/immunology , Troglitazone/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL